Cargando…

Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment

Clinical trials report substantial gains in visual acuity (VA) for eyes treated with intravitreal anti-VEGF for neovascular AMD (nAMD). In clinical reality, VA outcomes are more variable. Here we investigate pro-re nata treatment frequencies and VA in a real-life cohort of 1382 eyes (1048 patients)....

Descripción completa

Detalles Bibliográficos
Autores principales:	Wecker, Thomas, Grundel, Bastian, Reichl, Sabine, Stech, Milena, Lange, Clemens, Agostini, Hansjürgen, Böhringer, Daniel, Stahl, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397189/ https://www.ncbi.nlm.nih.gov/pubmed/30824721 http://dx.doi.org/10.1038/s41598-019-38934-8

Ejemplares similares

Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV
por: Wecker, Thomas, et al.
Publicado: (2017)

Real-life medium term follow-up data for intravitreal dexamethasone implant in retinal vein occlusion
por: Wecker, Thomas, et al.
Publicado: (2021)

OCT Angiography of the Choriocapillaris in Central Serous Chorioretinopathy: A Quantitative Subgroup Analysis
por: Cakir, Bertan, et al.
Publicado: (2019)

Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study
por: Bilgic, Alper, et al.
Publicado: (2021)

The Architecture of Macular Neovascularizations Predicts Treatment Responses to Anti-VEGF Therapy in Neovascular AMD
por: Faatz, Henrik, et al.
Publicado: (2022)

Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients
por: Ehlken, Christoph, et al.
Publicado: (2017)

Cataract surgery in neovascular AMD: impact on visual acuity and disease activity
por: Tang, Hin Yan, et al.
Publicado: (2023)

New Therapies of Neovascular AMD—Beyond Anti-VEGFs
por: Yerramothu, Praveen
Publicado: (2018)

Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study
por: Holz, F G, et al.
Publicado: (2016)

Optical Coherence Tomography Angiography to Distinguish Changes of Choroidal Neovascularization after Anti-VEGF Therapy: Monthly Loading Dose versus Pro Re Nata Regimen
por: Miere, Alexandra, et al.
Publicado: (2018)

Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol
por: Lin, Tiezhu, et al.
Publicado: (2020)

New Therapies of Neovascular AMD beyond Anti-VEGF Injections
por: Gahn, Greggory M., et al.
Publicado: (2018)

Associations with baseline visual acuity in 12,414 eyes starting treatment for neovascular AMD
por: Relton, S. D., et al.
Publicado: (2022)

Pro Re Nata Use of Psychotropic Medications in Assisted Living
por: Carder, Paula, et al.
Publicado: (2020)

The Impact of Interval between Recurrence and Reinjection in Anti-VEGF Therapy for Diabetic Macular Edema in Pro Re Nata Regimen
por: Takamura, Yoshihiro, et al.
Publicado: (2021)

A Randomized, Controlled Trial of Treat-and-Extend vs. Pro Re Nata Regimen for Neovascular Age-Related Macular Degeneration
por: Jia, Huixun, et al.
Publicado: (2022)

Associations with visual acuity outcomes after 12 months of treatment in 9401 eyes with neovascular AMD
por: Relton, SD, et al.
Publicado: (2022)

Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD
por: Fassnacht-Riederle, Heidi, et al.
Publicado: (2014)

Anti-VEGF intervention in neovascular AMD: benefits and risks restated as natural frequencies
por: Clearkin, Louis, et al.
Publicado: (2019)

Pro Re Nata Prescription and Perception Difference between Doctors and Nurses
por: Oh, Se Hwa, et al.
Publicado: (2014)

Pro re nata versus fixed aflibercept regimen for neovascular age-related macular degeneration: a systematic review and meta-analysis
por: Victor, Andi Arus, et al.
Publicado: (2022)

Topographical Analysis of the Choriocapillaris Reperfusion After Loading Anti-VEGF Therapy in Neovascular AMD
por: Viggiano, Pasquale, et al.
Publicado: (2022)

Patient Safety and Pro Re Nata Prescription and Administration: A Systematic Review
por: Vaismoradi, Mojtaba, et al.
Publicado: (2018)

Predicting Visual Acuity in Patients Treated for AMD
por: Marginean, Beatrice-Andreea, et al.
Publicado: (2022)

Incidence of ocular hypertension after intravitreal injection of anti-VEGF agents in the treatment of neovascular AMD
por: Moraru, Andreea, et al.
Publicado: (2017)

Influence of Psychotropic Pro Re Nata Drug Use on Outcomes in Hospitalized Patients with Schizophrenia
por: Kyou, Yoshitaka, et al.
Publicado: (2023)

Combination of AIBP, apoA-I, and Aflibercept Overcomes Anti-VEGF Resistance in Neovascular AMD by Inhibiting Arteriolar Choroidal Neovascularization
por: Zhang, Zhao, et al.
Publicado: (2022)

Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD
por: Chakravarthy, Usha, et al.
Publicado: (2021)

Ten-year real-world outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration using pro re nata regimen
por: Hujanen, Pekko, et al.
Publicado: (2023)

Sema3f Protects Against Subretinal Neovascularization In Vivo
por: Sun, Ye, et al.
Publicado: (2017)

Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD
por: Tsilimbaris, Miltiadis K., et al.
Publicado: (2016)

Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review
por: Khanna, Saira, et al.
Publicado: (2019)

The effect of systemic levels of TNF-alpha and complement pathway activity on outcomes of VEGF inhibition in neovascular AMD
por: Khan, Adnan H., et al.
Publicado: (2021)

The use and effectiveness of pro re nata psychotropic medications in children and adolescents: A systematic review
por: Asogwa, Kenneth, et al.
Publicado: (2017)

Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set
por: Lotery, A, et al.
Publicado: (2017)

Impact on Visual Acuity in Neovascular Age Related Macular Degeneration (nAMD) in Europe Due to COVID-19 Pandemic Lockdown
por: Arruabarrena, Carolina, et al.
Publicado: (2021)

Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis
por: Wu, Mingxing, et al.
Publicado: (2017)

Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab
por: Elwes, Flora, et al.
Publicado: (2018)

CNTF Prevents Development of Outer Retinal Neovascularization Through Upregulation of CxCl10
por: Bucher, Felicitas, et al.
Publicado: (2020)

A model to quantify the influence of treatment patterns and optimize outcomes in nAMD
por: Ziemssen, Focke, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ijkgdvojp4ii5uvu348ue6sodb